Merck ends Cholesterol drug study

pharmiweb.co.uk     22-May-2008            

Singapore, May 22, 2008: American pharma giant Merck has discontinued ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia... [read full story]                    

Full Coverage

ACHIEVE Imaging Study Discontinued

euroinvestor.co.uk     21-May-2008          

Merck & Co., Inc. today announced the discontinuation of ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The...                    

comments

                   

Merck Halts Study Of Experimental Cholesterol Drug

pharmiweb.co.uk     22-May-2008          

Co. discontinued a study of an experimental cholesterol drug after the trial's overseers concluded the patient population wasn't appropriate for the imaging technology being used to measure the drug's effectiveness. FDA also rejected Merck's proposed trade name for the product, Cordaptive, so...                    

comments

                   

Merck Can't ACHIEVE Anything

pharmiweb.co.uk     22-May-2008          

By Brian Orelli May 22, 2008 Comments (0) What do you get when you combine a trial design that failed to show improved patient outcomes, two cholesterol-lowering drugs, and an FDA not-approvable letter? Merck (NYSE: MRK) announced yesterday that it was cancelling its ACHIEVE (An Assessment of...                    

comments

Merck ends cholesterol drug study

pharmiweb.co.uk     23-May-2008          

Merck & Co has discontinued Achieve, an imaging study evaluating MK-0524A in patients with heterozygous familial hypercholesterolemia. The study was discontinued at the recommendation of the steering committee based on its review and evaluation of scientific data from recent carotid intima-media...                    

comments